Iron-chelating therapy with the new oral agent ICL670 (Exjade®)

Research output: Contribution to journalArticlepeer-review


Iron-chelation therapy is essential in iron-overloaded patients. The long-term efficacy of this approach has been demonstrated unequivocally with deferoxamine, which effectively controls iron concentrations, thereby limiting organ damage and preventing premature death. However, as deferoxamine is administered parenterally, poor compliance is a significant limitation to successful patient management. ICL670 (Exjade®) is a highly efficient and selective oral iron chelator. The results of phase I and phase II clinical studies indicate that ICL670 is at least as effective as current standard therapy (deferoxamine), with a tolerability and safety profile suitable for chronic, once-daily administration. These encouraging results have provided the rationale for the ongoing phase III programme, and offer physicians and patients the promise of an oral, once-daily, iron-chelating agent for the prevention and management of iron overload.

Original languageEnglish
Pages (from-to)289-298
Number of pages10
JournalBest Practice and Research: Clinical Haematology
Issue number2 SPEC. ISS.
Publication statusPublished - Jun 2005


  • Chelation therapy
  • Haemosiderosis
  • Iron overload
  • Iron-chelating agents

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Iron-chelating therapy with the new oral agent ICL670 (Exjade®)'. Together they form a unique fingerprint.

Cite this